Flavio A Cadegiani
Overview
Explore the profile of Flavio A Cadegiani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
445
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kerr L, Baldi F, Lobo R, Assagra W, Proenca F, Chamie J, et al.
Cureus
. 2022 Oct;
14(8):e28624.
PMID: 36196304
Background We have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 (COVID-19), irrespective of the regularity, in a strictly controlled citywide program in Southern Brazil (Itajaí, Brazil),...
2.
Cadegiani F
Cureus
. 2022 Aug;
14(8):e27883.
PMID: 35971401
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine-induced myocarditis is a rare but well-documented complication in young males. The increased incidence of sudden death among athletes following vaccination has...
3.
Santos H, Cadegiani F, Forbes S
Clin Ther
. 2022 Jul;
44(8):1129-1149.
PMID: 35810031
Purpose: Testosterone replacement and associated pharmacologic agents are effective strategies to treat male hypogonadism; however, nutraceutical agents and lifestyle modification approaches have gained medical interest. The purpose of this scoping...
4.
Kerr L, Cadegiani F, Baldi F, Lobo R, Assagra W, Proenca F, et al.
Cureus
. 2022 Apr;
14(3):c61.
PMID: 35371877
[This corrects the article DOI: 10.7759/cureus.21272.].
5.
Kerr L, Cadegiani F, Baldi F, Lobo R, Assagra W, Proenca F, et al.
Cureus
. 2022 Jan;
14(1):e21272.
PMID: 35070575
Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined...
6.
Cadegiani F, Zimerman R, Fonseca D, Correia M, Muller M, Bet D, et al.
Cureus
. 2022 Jan;
13(12):e20691.
PMID: 34976549
Background The role of androgens on COVID-19 is well established. Proxalutamide is a second-generation, non-steroidal antiandrogen (NSAA) with the highest antiandrogen potency among NSAAs and concurrent regulation of angiotensin-converting enzyme...
7.
Zimerman R, Cadegiani F, Pereira E Costa R, Goren A, de Souza B
Cureus
. 2021 Mar;
13(3):e13819.
PMID: 33728228
Background While public health strategies to contain the current coronavirus disease 2019 (COVID-19) pandemic are primarily focused on social distancing and isolation, emerging evidence suggest that in some regions social...
8.
Anderson T, Wideman L, Cadegiani F, Kater C
Int J Sports Physiol Perform
. 2021 Mar;
16(7):965-973.
PMID: 33662935
Purpose: To compare the CAR and diurnal cortisol slope between athletes diagnosed with OTS, healthy athletes, and sedentary controls. Methods: This study was a secondary analysis of data from the...
9.
Cadegiani F, McCoy J, Wambier C, Goren A
Cureus
. 2021 Mar;
13(2):e13047.
PMID: 33643746
Background and objective Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and subsequent infectivity are mediated by androgens and the androgen receptors through the regulation of transmembrane protease, serine...
10.
Cadegiani F, McCoy J, Wambier C, Vano-Galvan S, Shapiro J, Tosti A, et al.
Cureus
. 2021 Feb;
13(2):e13492.
PMID: 33633920
Background The entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into type II pneumocytes is dependent on a modification of viral spike proteins by transmembrane protease serine 2 (TMPRSS2)...